medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2014-18-27-33medsovet-795Research ArticleГОЛОВНАЯ БОЛЬ И ГОЛОВОКРУЖЕНИЕHEADACHE AND VERTIGOКак эффективнее купировать приступы мигрениHow to effectively treat migraine attacksГоловачеваВ. А.GolovachevaV. A.noemail@neicon.ruПарфеновВ. А.ParfyonovV. A.noemail@neicon.ruПервый Московский государственный медицинский университет им. И.М. СеченоваРоссияFirst Moscow State Medical University named after I.M. SechenovRussian Federation2014301220140182733Copyright © Головачева В.А., Парфенов В.А., 20142014Головачева В.А., Парфенов В.А.Golovacheva V.A., Parfyonov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/795

Мигрень - одна из наиболее частых причин нетрудоспособности людей молодого и среднего возраста. Многие пациенты с мигренью не удовлетворены препаратами, применяемыми для купирования приступа. Обсуждаются рациональный подход к лечению мигрени, эффективное купирование приступов мигрени. Анализируются препараты для лечения приступа мигрени с оценкой уровня доказательной эффективности. Изложены данные об эффективности и безопасности в купировании приступов мигрени Экседрина, содержащего 250 мг ацетилсалициловой кислоты, 250 мг парацетамола и 65 мг кофеина.

Migraine is one of the most common causes of disability of young and middle-aged people. Many patients with migraine are not satisfied with drugs used for the treatment. Rational approach to the treatment of migraine and effective relief of migraine attacks are discussed. Medicines for the treatment of migraine attacks and their evidence-based efficacy are analyzed. The efficacy and safety in relieving migraine of Excedrin containing 250 mg acetylsalicylic acid, 250 mg paracetamol and 65 mg caffeine, are described.

мигреньобезболивающие препаратытриптаныацетилсалициловая кислотапарацетамолкофеинЭкседринmigrainepain medicationstriptansacetylsalicylic acidparacetamolcaffeineExcedrReferencesBerg J, Stovner LJ. Cost of migraine and other headaches in Europe. European Journal of Neurology, 2005, 12 (suppl. 1): 59-67.Berg J, Stovner LJ. Cost of migraine and other headaches in Europe. European Journal of Neurology, 2005, 12 (suppl. 1): 59-67.Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G, Yakhno N, Steiner TJ. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia, 2012, 32 (5): 373-381.Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G, Yakhno N, Steiner TJ. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia, 2012, 32 (5): 373-381.Яхно Н.Н., Парфенов В.А., Алексеев В.В. Головная боль. М.: Р-Врач, 2000.Яхно Н.Н., Парфенов В.А., Алексеев В.В. Головная боль. М.: Р-Врач, 2000.Lipton RB, Stewart WF, Diamond S. et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache, 2001, 41 (7): 646-657.Lipton RB, Stewart WF, Diamond S. et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache, 2001, 41 (7): 646-657.Табеева ГР, Яхно Н.Н. Мигрень. М.: ГЭОТАР-Медиа, 2011.Табеева ГР, Яхно Н.Н. Мигрень. М.: ГЭОТАР-Медиа, 2011.Клинические рекомендации по неврологии Европейской федерации неврологических сообществ. (Пер. с англ.) Под ред. Gilhus NE, Barnes MP Brainin M. М.: АБВ-пресс, 2012.Клинические рекомендации по неврологии Европейской федерации неврологических сообществ. (Пер. с англ.) Под ред. Gilhus NE, Barnes MP Brainin M. М.: АБВ-пресс, 2012.Headache Classification Subcommittee of the International Headache Society. The international Classification of Headache Disorders, 3nd Edition (ICHD-3 beta). Cephalalgia, 2013, 33 (9): 629-808.Headache Classification Subcommittee of the International Headache Society. The international Classification of Headache Disorders, 3nd Edition (ICHD-3 beta). Cephalalgia, 2013, 33 (9): 629-808.Morey SS. Headache Consortium releases guidelines for use of CT or MRI in migraine work-up. Am. Fam. Physician, 2000, 63 (7): 1699-1701.Morey SS. Headache Consortium releases guidelines for use of CT or MRI in migraine work-up. Am. Fam. Physician, 2000, 63 (7): 1699-1701.Табеева ГР Практический подход к ведению больных с мигренью. РМЖ, 2008, 16 (17): 1129-1133.Табеева ГР Практический подход к ведению больных с мигренью. РМЖ, 2008, 16 (17): 1129-1133.Evers S, A'fra J, Frese A et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol, 2009, 16: 968-981.Evers S, A'fra J, Frese A et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol, 2009, 16: 968-981.Табеева ГР Кардиобезопасность триптанов в лечении приступов мигрени. Медицинский совет, 2014, 5: 16-20.Табеева ГР Кардиобезопасность триптанов в лечении приступов мигрени. Медицинский совет, 2014, 5: 16-20.Tfelt-Hansen P, Block G, Dahlof C et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia, 2000, 20: 765-786.Tfelt-Hansen P, Block G, Dahlof C et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia, 2000, 20: 765-786.Ellis GL, Delaney J, DeHart DA et al. The efficacy of metoclopramide in the treatment of migraine headache. Ann. Emerg. Med., 1993, 22: 191-195.Ellis GL, Delaney J, DeHart DA et al. The efficacy of metoclopramide in the treatment of migraine headache. Ann. Emerg. Med., 1993, 22: 191-195.Friedman BW, Corbo J, Lipton RB et al. A trial of metoclopramide vs sumatriptan for the emergency department of migraines. Neurology, 2005, 64: 463-468.Friedman BW, Corbo J, Lipton RB et al. A trial of metoclopramide vs sumatriptan for the emergency department of migraines. Neurology, 2005, 64: 463-468.Gilmore B, Michael M. Treatment of acute migraine headache. Am. Fam. Physician, 2011, 83 (3): 271-280.Gilmore B, Michael M. Treatment of acute migraine headache. Am. Fam. Physician, 2011, 83 (3): 271-280.Ferrari MD, Roon KI, Lipton RB et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet, 2001, 358 (9294): 1668-1675.Ferrari MD, Roon KI, Lipton RB et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet, 2001, 358 (9294): 1668-1675.Morey SS. Guidelines on migraine: part 2. General principles of drug therapy. Am. Fam. Physician, 2000, 62 (8): 1915-1917.Morey SS. Guidelines on migraine: part 2. General principles of drug therapy. Am. Fam. Physician, 2000, 62 (8): 1915-1917.Olesen C, Steffensen FH, Sorensen HT et al. Pregnancy outcome following prescription for sumatriptan. Headache, 2000, 40: 20-24.Olesen C, Steffensen FH, Sorensen HT et al. Pregnancy outcome following prescription for sumatriptan. Headache, 2000, 40: 20-24.Fox AW, Chambers CD, Anderson PO et al. Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache, 2002, 42: 8-15.Fox AW, Chambers CD, Anderson PO et al. Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache, 2002, 42: 8-15.Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs, 2003, 17: 1-7.Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs, 2003, 17: 1-7.Evans EW, Lorber KC. Use of 5-HT1 agonists in pregnancy. AnnPharmacother, 2008, 42: 543-549.Evans EW, Lorber KC. Use of 5-HT1 agonists in pregnancy. AnnPharmacother, 2008, 42: 543-549.Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain - three double-blind, randomized, placebo-controlled trials. Arch. Neurol., 1998, 55: 210-217.Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain - three double-blind, randomized, placebo-controlled trials. Arch. Neurol., 1998, 55: 210-217.Silberstein SD, Armellino JJ, Hoffman HD et al. Treatment of menstruation-associated migraine with the nonprescription combination of acetaminophen, aspirin, and caffeine: results from three randomized, placebo-controlled syudies. Clin. Ther., 1999, 21 (3): 475-491.Silberstein SD, Armellino JJ, Hoffman HD et al. Treatment of menstruation-associated migraine with the nonprescription combination of acetaminophen, aspirin, and caffeine: results from three randomized, placebo-controlled syudies. Clin. Ther., 1999, 21 (3): 475-491.Goldstein J, Silberstain SD, Saper JR et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache, 2005, 45 (8): 973-982.Goldstein J, Silberstain SD, Saper JR et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache, 2005, 45 (8): 973-982.Goldstein J, Silberstein SD, Saper JR et al. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a mul-ticenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache, 2006, 46 (3): 444-453.Goldstein J, Silberstein SD, Saper JR et al. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a mul-ticenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache, 2006, 46 (3): 444-453.

The authors declare that there are no conflicts of interest present.